Conlin and Carr have led trial teams in multibillion- and multimillion-dollar patent litigations, including Hatch-Waxman pharmaceutical patent litigation. They have successfully litigated and enforced the patent rights of global branded pharmaceutical, high technology, electronics, and software innovators.
“Dave’s and Kathleen’s reputations precede them, and the first-chair experience they will bring to our national practice is tremendous,” said Jonathan Sparks, Ph.D., chair of McCarter’s Intellectual Property group. “Their many talents, which have earned them respect and admiration in the business and legal communities, perfectly complement the full-service IP practice we have built to support our innovative life sciences, biotech, and technology clients and investors.”
“In addition to the opportunity to work with former colleagues on McCarter’s stellar IP team, Kathleen and I decided to join McCarter because of the firm’s reputation servicing innovative pharmaceutical companies,” adds Conlin. “We know their priorities are aligned with our focus on protecting every aspect of a client’s inventions. Also appealing is that McCarter has established patent litigators in Delaware and New Jersey, which are among the busiest patent litigation forums in the country.”
“McCarter is an outstanding firm with talented attorneys and a strong commitment to protecting innovation,” Carr said. “I am very excited to be joining the thriving McCarter team and look forward not only to working with McCarter’s exceptional group of IP professionals but also to accessing its broad range of services for clients with licensing, corporate, and other legal needs.”
“We are delighted to welcome Dave and Kathleen to our firm and to our Boston office. This strategic addition is a result of the firm’s growth initiative focusing, in part, on the Boston office and fueled by the firm’s record financial performance in the past few years,” commented Maria Laccotripe Zacharakis, Ph.D., McCarter’s Boston office managing partner.
Carr’s IP litigation practice focuses on patent, trademark, and copyright cases and disputes for clients ranging from major pharmaceutical companies to start-ups and senior executives. A registered U.S. patent attorney, Carr has successfully litigated and mediated patent cases for various clients in the pharmaceutical, biotechnology, medical devices, and technology sectors.
In addition to patent litigation, Carr has broad complex commercial litigation experience in cases involving admiralty and maritime law, insurance coverage disputes, and real estate.
Carr received her J.D. from Tulane University and her A.B. in Physics and A.B. in English from Dartmouth College. She is listed in Best Lawyers in America® for IP litigation and has been recognized as an LMG “Life Sciences Star” for IP litigation since its inaugural publication in 2012. The Legal 500 United States has also recognized her for Health Care: Life Sciences.
In addition to patent litigation, Conlin helps plan, establish, maintain, and enforce clients’ IP portfolios. His teams have driven the issuance of more than 3,800 patents. He has negotiated licenses for pharmaceutical, biotechnology, and technology companies. His teams have also achieved very favorable results in settlement, mediation, and other alternative dispute resolution procedures.
Conlin was technical advisor to Judge Baldwin at the U.S. Court of Customs and Patent Appeals (CCPA), predecessor court to the Federal Circuit. He also served as special master in the U.S. District Court for the District of New Hampshire.
Conlin received his J.D. from Georgetown University Law Center and his B.S. in Chemical Engineering from the State University of New York at Buffalo. He is regularly recognized for excellence in patent law and IP litigation and has been listed in Best Lawyers in America® for 30 consecutive years. Prior to his legal career, Conlin served as a patent examiner and worked as a chemical engineer at DuPont.
Prior to joining McCarter, Carr and Conlin were members at Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
About McCarter & English IP Practice
McCarter’s intellectual property professionals are as experienced and innovative when it comes to the development of strategies for protecting critical core technologies as they are in patenting new innovations. With more than 100 IP professionals, including close to 30 Ph.D.s, the group serves all facets of intellectual property development, maintenance, enforcement, regulation, and transactions. Our firm clients include some of the biggest names in the biotechnology, pharmaceutical, and technology fields, for whom we are building and managing complex patent portfolios; protecting blockbuster biotech and small-molecule drugs; and developing global strategic plans. For more information, visit www.mccarter.com.
Related media coverage includes the article below: